NICE Single Technology Appraisal Guidance No –
247 Tocilizumab for the treatment of rheumatoid arthritis
(rapid review of technology appraisal guidance 198)
This NICE guidance was published on 22 February 2012. The web
reference for the appraisal and other related documents is:
www.nice.org.uk/TA247
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (593/09) on
this medication for this indication in January 2010. This stated
that:
tocilizumab, (RoActemra) is accepted for
restricted use within NHS Scotland in combination with methotrexate
for the treatment of moderate to severe active rheumatoid arthritis
in adult patients who have either responded inadequately to, or who
were intolerant to, previous therapy with one or more
disease-modifying anti-rheumatic drugs or tumour necrosis factor
antagonists. It is restricted for use in combination therapy as no
economic case for monotherapy was presented.
Access the advice of SMC
3. There is no material difference between the
recommendations of the NICE STA and SMC. The NICE advice is
presented in the context of previous technology appraisals.
Share this content
Published Date: 22 February 2012
